The primary objective of the Informatics Core is to contribute to the science and operation of the Program Project by providing the informatics infrastructure and specialized technical expertise required to support the complex data integration and analysis needs of the grant. The scientific goals of the Projects are highly integrated and will require the analysis of shared data in an iterative fashion throughout the five years. The Core is split into two teams, each with its own faculty director. The University of Minnesota team (MN Team) is led by Dr. Sarah Cooley, Director of the Masonic Cancer Center Medical Informatics Shared Resources. The MN team is responsible for the development and maintenance of database applications to collect, integrate and report research data generated by the projects for subsequent analysis. In addition they will support and customize the clinical trials management application to meet the research and regulatory data requirements for the complex (phase I, IND, multi-center) trials in Projects 2 and 3. The sharing of research samples will be coordinated through this Core with a customized sample inventory management tool. Lastly, this team will develop and support the SOPs for data quality, data integrity, and data sharing, in compliance with HIPAA and caBIG principles. This team has collaborated in the development of the scientific plan by developing data collection and management plans specific to each aim, and will remain actively involved with each Project and Core throughout the life of this grant to monitor data quality and prepare datasets for analysis. The second team, led by Dr. Steven GE Marsh from the Anthony Nolan Trust, is responsible for the unique and specialized tools required for the storage, sharing and analysis of immunogenetic KIR data. The IPD-KIR database was established during the first cycle of this POI, and has proved a valuable resource for data analysis. They will confine to produce software tools to calculate KIR gene frequencies, allele frequencies and to estimate haplotypes and their frequencies at allelic level, define new alleles discovered by the Projects and Core D, and provide data crucial for the development of the high-resolution typing strategy to be employed in Project 1 (Parham) and Core D. Additionally they will provide sequence alignment tools for the analysis and visualization of the intergenic regions between KIR genes (Project 2). To support the clinical trials, they will develop a simple tool to predict the KIR haplotypes in any given individual, and indicate their content in terms of the centromeric and telomeric portions of the haplotype. The scientific expertise provided by this team will be invaluable to analyze and interpret immunogenetic data.

Public Health Relevance

The Program Project grant, which includes three clinical trials and multiple laboratory-based research studies, will generate significant amounts of complex data from mulfiple sites, all of which must be integrated for definifive analysis. This Core contains Faculty and staff at the University of Minnesota and from the Anthony Nolan Trust to develop and support the requisite informatics tools to support the clinical trials and basic research aims.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
United States
Zip Code
Cichocki, Frank; Verneris, Michael R; Cooley, Sarah et al. (2016) The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer. Curr Top Microbiol Immunol 395:225-43
He, F; Warlick, E; Miller, J S et al. (2016) Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGvHD. Bone Marrow Transplant 51:1107-12
Weisdorf, Daniel (2016) The role of second transplants for leukemia. Best Pract Res Clin Haematol 29:359-364
Sarhan, Dhifaf; Cichocki, Frank; Zhang, Bin et al. (2016) Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells. Cancer Res 76:5696-5706
Felices, Martin; Miller, Jeffrey S (2016) Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise? Clin Cancer Res 22:5161-5163
Schmohl, Joerg U; Felices, Martin; Taras, Elizabeth et al. (2016) Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker. Mol Ther 24:1312-22
Horowitz, Amir; Guethlein, Lisbeth A; Nemat-Gorgani, Neda et al. (2015) Regulation of Adaptive NK Cells and CD8 T Cells by HLA-C Correlates with Allogeneic Hematopoietic Cell Transplantation and with Cytomegalovirus Reactivation. J Immunol 195:4524-36
Holtan, Shernan G; Verneris, Michael R; Schultz, Kirk R et al. (2015) Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. Biol Blood Marrow Transplant 21:1029-36
Holtan, Shernan G; DeFor, Todd E; Lazaryan, Aleksandr et al. (2015) Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 125:1333-8
Schlums, Heinrich; Cichocki, Frank; Tesi, Bianca et al. (2015) Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 42:443-56

Showing the most recent 10 out of 74 publications